Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Memorial Sloan Kettering Cancer Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1678
Shown on this page
12
Current sort
Recently updated
Campus scope
Memorial Sloan Kettering Cancer Center, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Memorial Sloan Kettering Cancer Center, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 517–528 of 1,678 matching trials with a site at Memorial Sloan Kettering Cancer Center, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Not applicable Interventional

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

NCT06037941
Status at this site: Recruiting
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
E-Nose testing, Research blood
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
30 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

NCT06660654
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumors
Interventions
Raludotatug deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Marietta, Georgia • Ann Arbor, Michigan • East Brunswick, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07116616
Status at this site: Recruiting
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
mRNA-2808
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)

NCT05814549
Site status not listed — check the official record
View directory record Official record
Conditions
Oropharyngeal Cancer, HPV-Related Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
NavDx
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
45 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Active, not recruiting Phase 1 Interventional

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

NCT04044859
Site status not listed — check the official record
View directory record Official record
Conditions
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
Interventions
Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
Genetic
Lead sponsor
USWM CT, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2037
U.S. locations
9
States / cities
Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Recruiting Phase 2 Interventional

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

NCT04684368
Status at this site: Recruiting
View directory record Official record
Conditions
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
Interventions
Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 29 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Recruiting Phase 2 Interventional

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

NCT06175000
Status at this site: Recruiting
View directory record Official record
Conditions
Primary Central Nervous System Lymphoma
Interventions
Cognitive Assessment, Obinutuzumab, Quality of Life Assessment
Procedure · Biological · Other
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
New York, New York • Cleveland, Ohio • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401
Site status not listed — check the official record
View directory record Official record
Conditions
Solid Tumors, CNS Tumors
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Active, not recruiting Phase 3 Interventional

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

NCT04662255
Site status not listed — check the official record
View directory record Official record
Conditions
Lymphoma, Mantle-Cell
Interventions
Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
36
States / cities
Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Advancing Nursing Practices in Hospital Oncology Care

NCT05053191
Site status not listed — check the official record
View directory record Official record
Conditions
Gastrointestinal Cancer, Gastrointestinal Disease, Nurse's Role
Interventions
Partnership, Assessment, Care and Transition training intervention
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Recruiting Phase 2 Interventional

A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer

NCT07631000
Status at this site: Recruiting
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal-junction Cancer
Interventions
Cadonilimab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:35 AM EDT
Recruiting Phase 2 Interventional

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

NCT05607108
Status at this site: Recruiting
View directory record Official record
Conditions
Squamous Cell Lung Cancer
Interventions
ZEN003694
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 10:35 AM EDT

About this Memorial Sloan Kettering Cancer Center institution page

What this page lists
ClinicalTrials.gov records that list Memorial Sloan Kettering Cancer Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Memorial Sloan Kettering Cancer Center at any site, browse by condition, or browse by U.S. city.